Waller D G, Mihindukulasuriya J, Warren D J
Br J Clin Pharmacol. 1985 Jan;19(1):37-43. doi: 10.1111/j.1365-2125.1985.tb02610.x.
Intravenous loading with 500 ml of 2.7% saline increased the clearance of PAH and inulin and urine sodium excretion in 14 healthy subjects. Intravenous propranolol (0.075 and 0.15 mg/kg) did not alter PAH or inulin clearance at rest but abolished the increase expected during saline infusion. There was no consistent effect on urinary sodium excretion. Intravenous nadolol (0.05 and 0.75 mg/kg) reduced resting PAH and inulin clearances by up to 25%. Both clearances fell significantly during saline infusion but natriuresis was not significantly reduced in spite of the changes in renal function. There was no evidence from these studies in normal volunteers that nadolol confers any advantages over propranolol in its effects on renal function.
对14名健康受试者静脉输注500毫升2.7%的盐水进行负荷试验,可增加对氨基马尿酸(PAH)和菊粉的清除率以及尿钠排泄量。静脉注射普萘洛尔(0.075和0.15毫克/千克)在静息状态下不会改变PAH或菊粉的清除率,但会消除盐水输注期间预期的清除率增加。对尿钠排泄没有一致的影响。静脉注射纳多洛尔(0.05和0.75毫克/千克)可使静息状态下的PAH和菊粉清除率降低多达25%。在盐水输注期间,两种清除率均显著下降,但尽管肾功能发生了变化,利钠作用并未显著降低。在正常志愿者的这些研究中,没有证据表明纳多洛尔在对肾功能的影响方面比普萘洛尔有任何优势。